Volumetric tumor growth in advanced non‐small cell lung cancer patients with EGFR mutations during EGFR‐tyrosine kinase inhibitor therapy
Open Access
- 6 August 2013
- Vol. 119 (21), 3761-3768
- https://doi.org/10.1002/cncr.28290
Abstract
BACKGROUND The objective of this study was to define the volumetric tumor growth rate in patients who had advanced nonsmall cell lung cancer (NSCLC) with sensitizing epidermal growth factor receptor (EGFR) mutations and had initially received treatment with EGFR‐tyrosine kinase inhibitor (TKI) therapy beyond progression. METHODS The study included 58 patients with advanced NSCLC who had sensitizing EGFR mutations treated with first‐line gefitinib or erlotinib, had baseline computed tomography (CT) scans available that revealed a measurable lung lesion, had at least 2 follow‐up CT scans during TKI therapy, and had experienced volumetric tumor growth. The tumor volume (in mm3) of the dominant lung lesion was measured on baseline and follow‐up CT scans during therapy. In total, 405 volume measurements were analyzed in a linear mixed‐effects model, fitting time as a random effect, to define the growth rate of the logarithm of tumor volume (logeV). RESULTS A linear mixed‐effects model was fitted to predict the growth of logeV, adjusting for time in months from baseline. LogeV was estimated as a function of time in months among patients whose tumors started growing after the nadir: logeV = 0.12*time + 7.68. In this formula, the regression coefficient for time, 0.12/month, represents the growth rate of logeV (standard error, 0.015/month; P < .001). When adjusted for baseline volume, logeV0, the growth rate was also 0.12/month (standard error, 0.015/month; P < .001; logeV = 0.12*months + 0.72 logeV0 + 0.61). CONCLUSIONS Tumor volume models defined volumetric tumor growth after the nadir in patients with EGFR‐mutant, advanced NSCLC who were receiving TKI, providing a reference value for the tumor growth rate in patients who progress after the nadir on TKI therapy. The results can be studied further in additional cohorts to develop practical criteria to help identify patients who are slowly progressing and can safely remain on EGFR‐TKIs. Cancer 2013;119:3761–3768. © 2013 American Cancer Society.Keywords
This publication has 56 references indexed in Scilit:
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trialThe Lancet Oncology, 2012
- Tumour growth rates and RECIST criteria in early drug developmentEuropean Journal of Cancer, 2011
- Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyThe Lancet Oncology, 2011
- Imaging of Lung Cancer in the Era of Molecular MedicineAcademic Radiology, 2011
- CT Tumor Volume Measurement in Advanced Non-small-cell Lung Cancer: Performance Characteristics of an Emerging Clinical ToolAcademic Radiology, 2011
- Gefitinib or Carboplatin–Paclitaxel in Pulmonary AdenocarcinomaThe New England Journal of Medicine, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancerAnnals Of Oncology, 2006
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinibProceedings of the National Academy of Sciences of the United States of America, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibThe New England Journal of Medicine, 2004